October 10, 2024

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , Oct. 10, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024 ,
October 3, 2024

Labcorp Biopharmaceutical CMC Services Subunit vaccines: Analytical techniques for characterization, release and stability testing

Since the development of the first vaccines that comprised inactive or attenuated pathogens, there has been a drive to continue to produce safer vaccine formulations that are more effective, cause fewer side effects and are safer overall. This has resulted in the development of a wide range of vaccine modalities, including viral vector-based component vaccines and DNA/RNA vaccines. One consequence of this has been the development of subunit vaccines, which are more chemically defined and have an enhanced safety profile. Subunit vaccines are vaccines that contain only the antigenic component(s) of a pathogen.
October 7, 2024

Accelerating CAR T-cell therapy clinical trial timelines with comprehensive biomarker-driven strategies

Chimeric antigen receptor (CAR) T-cell therapy is one of the fastest-growing sectors within oncology therapeutic development. This advanced form of immunotherapy can deliver “designer” T-cells to specifically recognize, and attack, cancer based on unique tumor-associated antigens, offering a highly targeted and personalized approach. Recently, adoptive cell therapy (ACT) has received considerable attention due to the success of CAR T-cell therapy in treating hematological malignancies. This article focuses on CAR T-cell therapies in cancer and discusses how biopharmaceutical companies can leverage a comprehensive biomarker strategy for their drug development programs to accelerate clinical trial timelines and better predict clinical outcomes.
October 7, 2024

Six FDA recommendations on NAMs

Summary

To help guide best approaches to new approach methods, the FDA has released "Potential Approaches to Drive Future Integration of New Alternative Methods for Regulatory Decision-Making," the latest report detailing recommendations from a NAMs subcommittee of the FDA Science Board. Download the full report for the six recommendations.

<span>Three ways to strengthen the immune system</span>
October 7, 2024

Three ways to strengthen the immune system

What if instead of referring to the next few months as flu season, we reframed our perspective and referred to this time as immune system empowerment season? While it doesn’t necessarily roll off the tongue, it certainly represents a more proactive and action-oriented approach in fighting off many of the illnesses associated with fall weather.